New treatment for kidney problems caused by alcoholic liver disease
Official title: Novel therapy for alcoholic liver disease-associated hepatorenal syndrome
Funded at Mitopower LLC · NIH-10920469 · Data updated 2026-11-12
This study is testing a new treatment using a supplement called nicotinamide riboside to help improve kidney and liver health in people with hepatorenal syndrome caused by alcoholic liver disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mitopower LLC NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project start | September 25, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,500,000 |
| NIH project number | 5U44AA029833-04 |
| Project ID | NIH-10920469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with alcoholic liver disease who are experiencing hepatorenal syndrome.
✕Less likely to help
Patients with liver disease not related to alcohol or those without kidney complications may not benefit from this research.
What this research studies
This research investigates a novel therapy aimed at treating hepatorenal syndrome, a serious condition that can occur in patients with alcoholic liver disease. The approach focuses on addressing the cellular dysfunction and inflammation that lead to kidney failure by using a supplement called nicotinamide riboside (NR) to boost levels of a critical molecule known as NAD+. By enhancing mitochondrial function and reducing organ damage, the therapy aims to improve kidney and liver health in affected patients. The research utilizes animal models to evaluate the effectiveness of this treatment before considering human trials.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from kidney failure related to alcoholic liver disease.
How similar studies have gone: Previous studies have shown promising results with NAD+ supplementation in animal models, indicating potential for success in this novel approach.
Where this research is happening
-
Mitopower LLC
Palo Alto, United States Active
Researchers
- Principal investigator: Subramanian, Mani — Mitopower LLC
- Study coordinator: Subramanian, Mani
Related research
Other NIH-funded projects on the same topics.
-
Microbiome and Innate Immune Response in Alcohol-Related Liver Disease
Researchers are studying how gut bacteria and the body's first-line immune defenses contribute to liver damage from alcohol, with a focus on how a specific bacteria and its toxins affect disease severity.
-
Lipotoxicity and Alcohol-Related Liver Disease
This project studies how fatty acids cause liver cell damage in alcohol-related liver disease to help develop new treatments.
-
NNMT as a Target to Treat Alcoholic Liver Disease
A study to see if blocking an enzyme called NNMT can help people with alcoholic liver disease.
-
How gut fungi may drive alcohol-related liver damage
Researchers are looking at whether specific fungi in the gut make liver damage from heavy drinking worse in people with alcohol-related liver disease.
-
Heat shock protein 90 and alcohol-related liver disease: how macrophages fuel inflammation
This project looks at how a cellular stress protein, HSP90, affects liver inflammation in people with alcohol-related liver disease by focusing on macrophages.
-
Why alcohol-related liver disease can come back after a transplant
Looking at whether an enzyme called CerS6 helps fat build up in the liver and whether measuring CerS6 can help detect or predict return of alcohol-related liver disease before or after a liver transplant.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.